Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Diffuse scleroderma
- Focus Therapeutic Use
- 07 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 07 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.